Prognostic Nomograms for Patients with Primary Sarcomatoid Carcinoma of The Urinary Bladder: Based on The SEER Database
Urology Journal,
Vol. 20 (2023),
25 December 2022
,
Page 7595
https://doi.org/10.22037/uj.v20i.7595
Abstract
Purpose: The present study aimed to develop nomograms based on the SEER database to predict the prognosis for patients with primary sarcomatoid carcinoma of the urinary bladder (SCUB).
Materials and Methods: Patients with primary SCUB was identified in the Surveillance, Epidemiology, and End Results (SEER) database, between 1975 and 2017. Univariate and multivariable Cox analysis were conducted to identify the independent prognostic factors for developing the overall survival (OS) and cancer-specific survival (CSS) nomograms. Then, concordance index (C-index), receiver operating characteristic (ROC) curve and calibration curve were used to evaluate the accuracy of the nomogram model. In addition, the model was further compared with TNM staging system.
Results: A total of 238 eligible patients with primary SCUB were selected from the SEER database. As suggested by Cox-analysis, age, sex, T stage, M stage, tumor size, and surgery type of primary site were identified as the independent factors for predicting both OS and CSS. We developed OS and CSS nomograms with a favorable C-index by using these prognostic factors. The C-indexes of the OS and CSS nomogram in present study were 0.738 (0.701-0.775) and 0.763 (0.724-0.802), which were superior to those of the AJCC TNM staging with 0.621 (0.576-0.666) and 0.637 (0.588-0.686) respectively, showing better discriminatory ability. Subsequently, the ROC curves showed that the 1-, 3- and 5-year AUCs (area under curve) of OS nomogram (i.e., 0.793, 0.807 and 0.793) were higher than those of the TNM stage((i.e., 0.659, 0.676, 0.659). Similarly, as for CSS model, them ((i.e., 0.823, 0.804 and 0.804) were aslo exceed those of TNM stage((i.e., 0.683, 0.682, 0.682). Furthermore, the calibration curves indicated a good consistency between the predictive survival and the actual survival. Finally, patients were stratified by risk, and Kaplan-Meier survival curve suggested that the prognosis of the low-risk group was significantly better than that of the high-risk group.
Conclusion: We developed nomograms with the SEER database, which could help predict the prognosis of SCUB individuals more accurately.
- nomogram, sarcomatoid carcinoma, bladder cancer, SEER, prognostic analysis
How to Cite
References
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71: 209- 49.
Nigwekar P, Amin MB. The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Adv Anat Pathol. 2008;15:218-33.
Humphrey PA, Moch H, Cubilla AL, et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016;70:106-19.
DENT ED Jr. Carcinosarcoma (collision tumor) of the urinary bladder. J Urol.1955;74:104-8.
Sanfrancesco J, McKenney JK, Leivo MZ, Gupta S, Elson P, Hansel DE. Sarcomatoid Urothelial Carcinoma of the Bladder: Analysis of 28 Cases With Emphasis on Clinicopathologic Features and Markers of Epithelial-to-Mesenchymal Transition. Arch Pathol Lab Med. 2016;140:543-51.
Eble JN, Sauter G, Epstein JI, Sesterhen IA. World Health Organization Classification fo Tumour. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs.IARC Press. 2004.
Wright JL, Black PC, Brown GA, et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007;178:2302-6; discussion 2307.
Cheng L, Zhang S, Alexander R, et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol. 2011;35:e34-46.
Fatima N, Canter DJ, Carthon BC, et al. Osunkoya AO. Sarcomatoid urothelial carcinoma of the bladder: a contemporary clinicopathologic analysis of 37 cases. Can J Urol. 2015;22:7783-7.
Wang J, Wang FW, Lagrange CA, Hemstreet Iii GP, Kessinger A. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma, 2010;2010:454792.
Malla M, Wang JF, Trepeta R, Feng A, Wang J. Sarcomatoid Carcinoma of the Urinary Bladder. Clin Genitourin Canc. 2016;1:366-72.
Sui W, Matulay JT, Onyeji IC, et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol. 2017;35:1055-61.
Torenbeek R, Blomjous CE, de Bruin PC, Newling DW, Meijer CJ. Sarcomatoid carcinoma of the urinary bladder. Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol. 1994;18:241-9.
Robinson SP, Farooq A, Laniado M, Motiwala H. The demographic features, clinical outcomes, prognosis and treatment options for patients with sarcomatoid carcinoma of the urinary bladder: a single centre experience. Int Braz J Urol. 2018;44:45-52.
Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009; 22:S96-118.
Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship. Am J Surg Pathol. 2016;40:e94-102.
Diao JD, Ma LX, Wu CJ, et al. Construction and validation a nomogram to predict overall survival for colorectal signet ring cell carcinoma. Sci Rep. 2021;11:3382.
Xu Z, Wang L, Tu L, et al. Epidemiology of and prognostic factors for patients with sarcomatoid carcinoma: a large population-based study. Am J Cancer Res. 2020;10:3801-14.
Wagner MJ, Chau B, Loggers ET, et al. Long-term Outcomes for Extraskeletal Myxoid Chondrosarcoma: A SEER Database Analysis. Cancer Epidem Biomar. 2020;29:2351-7.
Leone JP, Graham N, Tolaney SM, et al. Estimating long-term mortality in women with hormone receptor-positive breast cancer: The 'ESTIMATE' tool. Eur J Cancer. 2022;173:20-9.
Andrade KC, Khincha PP, Hatton JN, et al. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study. Lancet Oncol. 2021;22:1787-98.
Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018;73:560-9.
Park JH, Moon KC. Tumor, Nodes, Metastases (TNM) Classification System for Bladder Cancer. Bladder Cancer. 2018;1:181-4.
Wang J, Wu Y, He W, Yang B, Gou X. Nomogram for predicting overall survival of patients with bladder cancer: A population-based study. Int J Biol Markers. 2020;35:29-39.
Hu MD, Chen SH, Liu Y, Jia LH. Development and validation of a nomogram to predict the prognosis of patients with squamous cell carcinoma of the bladder. Biosci Rep.2019;39:BSR20193459.
Megwalu II, Vlahiotis A, Radwan M, Piccirillo JF, Kibel AS. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol. 2008;53:581-9.
Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173-80.
Morlacco A, Modonutti D, Motterle G, Martino F, Dal Moro F, Novara G. Nomograms in Urologic Oncology: Lights and Shadows. J Clin Med. 2021;10:980.
Osawa T, Abe T, Takada N, Ito YM, Murai S, Shinohara N. Validation of the nomogram for predicting 90-day mortality after radical cystectomy in a Japanese cohort. Int J Urol. 2018;25:699-700.
Hirabayashi S, Kosugi S, Isobe Y, et al. Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer. Ann Oncol. 2014;25:1179-84.
Berardi G, Morise Z, Sposito C, et al. Development of a nomogram to predict outcome after liver resection for hepatocellular carcinoma in Child-Pugh B cirrhosis. J Hepatol. 2020;72:75-84.
Kim SY, Cho N, Choi Y, et al. Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram. Radiology. 2021;299:290-300.
Fakhry C, Zhang Q, Nguyen-Tân PF, et al. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. J Clin Oncol. 2017;35:4057-65.
Zhang Y, Hong YK, Zhuang DW, He XJ, Lin ME. Bladder cancer survival nomogram: Development and validation of a prediction tool, using the SEER and TCGA databases. Medicine (Baltimore). 2019;98:e17725.
Aziz A, May M, Burger M, et al. Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol. 2014; 66:156-63.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471-4.
Mori K, Abufaraj M, Mostafaei H, et al. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. J Urol. 2020;204:1129-40.
Claps F, Kamp MW, Mayr R, et al. Risk factors associated with positive surgical margins' location at radical cystectomy and their impact on bladder cancer survival. World J Urol. 2021;39:4363-71.
Lee YH, Bang H, Kim DJ. How to Establish Clinical Prediction Models. Endocrinol Metab (Seoul). 2016;31:38-44.
Claps F, Mir MC, Zargar H. Molecular markers of systemic therapy response in urothelial carcinoma. Asian J Urol. 2021;8:376-90.
Mir MC, Campi R, Loriot Y, et al. Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities. Eur Urol Oncol. 2022;5:726-31.
- Abstract Viewed: 79 times
- Just Accepted-7595 Downloaded: 45 times